Lipid Nanoparticle Delivery Patent Landscape 2026
Lipid Nanoparticle Delivery Patent Landscape in 2026
The lipid nanoparticle (LNP) delivery field is in a sustained growth phase, with multi-year filing volume more than doubling compared to the prior window, though annual output eased from its 2023 peak. ModernaTX leads a concentrated but deeply competitive field anchored by a tight cluster of US biotech firms and academic institutions, with genetic-medicine delivery as the dominant technology route.
ModernaTX leads a concentrated US-anchored field
ModernaTX holds the top position in the applicant ranking, followed closely by Alnylam Pharmaceuticals and Massachusetts Institute of Technology. The top five filers together account for a quarter of the combined output of the hundred largest filers, signalling meaningful but not monopolistic concentration.
The first tier—ModernaTX, Alnylam, MIT, The Broad Institute, and Translate Bio—is closely spaced, with no single player commanding an insurmountable lead. A dense second tier of academic medical centers, gene-editing specialists, and RNA therapeutics companies sits just behind, keeping competitive pressure high across the ranking.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | ModernaTX Inc | 2,021 | |
| 2 | Alnylam Pharmaceuticals Inc | 1,868 | |
| 3 | Massachusetts Institute of Technology | 1,636 | |
| 4 | The Broad Institute Inc | 1,215 | |
| 5 | Translate Bio Inc | 1,172 | |
| 6 | Regents of the University of California | 961 | |
| 7 | Intellia Therapeutics Inc | 911 | |
| 8 | PRESIDENT & FELLOWS OF HARVARD COLLEGE | 807 | |
| 9 | Board of Regents, The University of Texas System | 780 | |
| 10 | The Trustees of the University of Pennsylvania | 755 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Regeneron Pharmaceuticals Inc | 719 | |
| 12 | Dicerna Pharmaceuticals Inc | 683 | |
| 13 | Voyager Therapeutics Inc | 660 | |
| 14 | Flagship Pioneering Innovations VI LLC | 658 | |
| 15 | Generation Bio Co | 635 | |
| 16 | Selecta Biosciences Inc | 590 | |
| 17 | Acuitas Therapeutics Inc | 530 | |
| 18 | CRISPR Therapeutics AG | 486 | |
| 19 | The Board of Trustees of the Leland Stanford Junior University | 483 | |
| 20 | EmendoBio Inc | 452 |
The leaders’ positions reflect a field where platform breadth (formulation chemistry, cargo type, therapeutic indication) differentiates more than raw volume. Any entrant must contend with deep portfolios spanning lipid chemistry, delivery biology, and clinical application claims.
The most recent 18–24 months of data are likely under-counted due to patent publication lag; apparent softening in 2024–2025 should not be interpreted as a real decline in activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Multi-year expansion with a genetic-medicine technology core
Annual filing volume grew sharply from 2017 through 2023 before easing; the technology mix is dominated by medicinal preparation and genetic engineering branches, with a long tail of adjacent chemistry classes.
Annual filing trend
Filings climbed steadily from 2017 through a 2023 peak before easing in 2024–2025. The recent-window total is roughly double the prior-window total, confirming the field’s growth-stage status. Data for 2024 onward is further suppressed by publication lag and should not be read as a structural decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61K (medicinal preparations) and C12N (microorganisms and genetic engineering) jointly dominate the branch mix, reflecting LNP’s dual role as a formulation platform and a gene-therapy enabler. A61P (therapeutic activity) ranks third, underscoring the clinical-application breadth. Downstream chemistry branches—C07K (peptides and proteins), C07C (acyclic compounds), C07D (heterocyclic compounds)—appear at lower but non-trivial shares, pointing to active lipid-component innovation.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
DNA Vector Delivery Using Lipid Nanoparticles
The present disclosure provides a lipid nanoparticle comprising encapsulated DNA vector and 30 to 60 mol % of a neutral lipid selected from sphingomyelin and a phosphatidylcholine lipid, and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle comprising a core comprising an electron dense region and an aqueous portion… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Delivery, engineering and optimization of systems,… | 1,479 |
| 2 | Novel lipids and lipid nanoparticle formulations f… | 1,040 |
| 3 | Delivery, engineering and optimization of systems,… | 976 |
| 4 | Novel lipids and lipid nanoparticle formulations f… | 922 |
| 5 | Novel crispr enzymes and systems | 856 |
| 6 | Cleavable lipids | 821 |
| 7 | CRISPR enzymes and systems | 748 |
| 8 | Lipids for the delivery of active agents | 745 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the competitive structure means for R&D investment
The field’s growth trajectory, concentrated leadership, dense academic-industry collaboration network, and US-centric filing geography each carry distinct implications for where and how new R&D investment can gain traction.
Growth stage — expanding but past peak annual volume
The field is classified as Growth: recent three-year filing volume sits roughly double the prior three-year window. Annual output peaked in 2023 and has eased since, a pattern consistent with a maturing growth field rather than contraction. New entrants face an established prior-art landscape but the technology frontier—particularly in non-liver targeting and next-generation ionizable lipids—remains actively contested.
Growth stageTop five hold a quarter of the leading-hundred filers’ output
The top five filers’ share of the hundred largest filers stands at 25%, indicating moderate-to-high concentration without a single dominant incumbent. The second tier is dense—ten or more players with meaningful portfolios—which keeps licensing and freedom-to-operate negotiations complex. A new platform or formulation differentiated at the lipid-chemistry or cargo-biology level has room to establish a distinct position.
Moderate concentrationMIT–Broad–Harvard triangle anchors co-filing activity
The most active co-filing pairs are MIT and The Broad Institute (605 joint records), The Broad Institute and Harvard (301), and MIT and Harvard (277). CRISPR Therapeutics and Bayer Healthcare represent the leading industry–industry co-filing pair (69 records), while Intellia Therapeutics and Regeneron account for 38. These clusters signal that platform-level IP in LNP-enabled gene editing is being built through structured academic-industry partnerships rather than in-house alone.
Academic-industry clustersUS and PCT filings dominate; Europe is a meaningful secondary market
The United States is the primary filing jurisdiction, followed by WIPO PCT and Europe via the EPO. Australia and Canada constitute a secondary ring of protection, consistent with major clinical-trial and regulatory markets. Singapore appears as a notable Asia-Pacific filing destination. The concentration in Western jurisdictions suggests that Asia-based entrants with strong local prosecution strategies may find less crowded ground in some markets.
US-led, PCT broadGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Massachusetts Institute of Technology | The Broad Institute Inc | 605 |
| The Broad Institute Inc | President and Fellows of Harvard College | 301 |
| Massachusetts Institute of Technology | President and Fellows of Harvard College | 277 |
| CRISPR Therapeutics AG | Bayer Healthcare LLC | 69 |
| Intellia Therapeutics Inc | Regeneron Pharmaceuticals Inc | 38 |
| The Broad Institute Inc | Rutgers University | 27 |
| President and Fellows of Harvard College | Rutgers University | 27 |
| Massachusetts Institute of Technology | Rutgers University | 25 |
| Massachusetts Institute of Technology | Fujifilm Corporation | 25 |
| The Broad Institute Inc | University of Iowa Research Foundation | 23 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
ModernaTX and Alnylam lead; University of Pennsylvania accelerating
The leader board spans dedicated RNA therapeutics companies, gene-editing specialists, and research universities, each with a distinct technology emphasis. Momentum diverges sharply across the top tier.
ModernaTX Inc
ModernaTX leads the ranking with 2,021 patent records, concentrated in medicinal preparation formulations (A61K9) and genetic engineering (C12N15). Recent-period filing trend shows –11% versus the prior window, suggesting a consolidation phase after rapid portfolio expansion. The breadth of their formulation and mRNA cargo claims makes them the most comprehensive single-entity filer in the corpus.
patent records: 2,021University of Pennsylvania
Penn ranks tenth overall with 755 patent records but is the fastest-growing major player in the recent window, up +142% versus the prior period. Their focus spans genetic engineering (C12N15), medicinal preparations (A61K9), and small-molecule adjuncts (A61K31), reflecting broad platform work rather than a single therapeutic modality. This trajectory suggests Pennsylvania is actively building foundational IP across LNP cargo and formulation chemistry.
patent records: 755| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| ModernaTX Inc | 314 | ▼ -11% |
| Massachusetts Institute of Technology | 180 | ▬ -5% |
| The Broad Institute Inc | 130 | ▬ +4% |
| Translate Bio Inc | 89 | ▼ -75% |
| Intellia Therapeutics Inc | 165 | ▲ +12% |
| The Trustees of the University of Pennsylvania | 235 | ▲ +142% |
| President and Fellows of Harvard College | 80 | ▲ +23% |
| Generation Bio Co | 125 | ▼ -32% |
Under-served branches adjacent to the LNP core
Several IPC branches adjacent to the dominant medicinal-preparation and genetic-engineering core show comparatively low filing share relative to their technical relevance to LNP delivery, making them worth monitoring for whitespace.
C12Q · Measuring and testing involving enzymes/DNA
C12Q accounts for a small share of the corpus despite LNP delivery being central to nucleic-acid diagnostics and in vivo gene-expression assays. The branch covers enzymatic and DNA-based measurement methods, which are directly applicable to validating LNP cargo delivery efficiency and endosomal escape. Teams developing LNP-based diagnostic or companion-assay tools could find meaningful room to stake claims in this adjacent space before it fills.
Search this in Eureka →B82Y · Nanotechnology applications
B82Y captures nanotechnology-specific application claims and holds a modest share of the corpus despite LNP being, by definition, a nanotechnology platform. The sparsity likely reflects applicants filing primarily under pharmaceutical and chemistry codes rather than nanotechnology codes, but it also represents an under-claimed framing for LNP innovations—particularly those involving hybrid nanostructures, surface functionalization, or organ-selective targeting via nanoparticle engineering. This framing may be strategically useful in jurisdictions with distinct nanotechnology patent pathways.
Search this in Eureka →How leaders differ by technology route
Strength of each leader across the main technology routes.
| Player | C12N 15 · Microorganisms & genetic engineering | A61K 9 · Medicinal preparations | A61K 31 · Medicinal preparations | A61K 47 · Medicinal preparations | A61K 48 · Medicinal preparations |
|---|---|---|---|---|---|
| ModernaTX Inc | Strong · 591 | Strong · 821 | Strong · 482 | Moderate · 344 | Moderate · 402 |
| Translate Bio Inc | Strong · 293 | Strong · 520 | Moderate · 245 | Moderate · 172 | Strong · 282 |
| Massachusetts Institute of Technology | Strong · 749 | Emerging · 114 | Emerging · 96 | Emerging · 92 | Moderate · 236 |
| The Broad Institute Inc | Strong · 647 | Absent | Absent | Absent | Emerging · 126 |
| Selecta Biosciences Inc | Absent | Strong · 210 | Strong · 191 | Strong · 189 | Absent |
| Generation Bio Co | Strong · 276 | Moderate · 125 | Absent | Absent | Strong · 148 |
| The Trustees of the University of Pennsylvania | Absent | Strong · 210 | Strong · 141 | Strong · 122 | Absent |
Frequently asked questions
The corpus covers 17,357 patent families globally. The United States is the primary filing jurisdiction, followed by WIPO PCT and Europe via the EPO.
ModernaTX Inc holds the top position in the applicant ranking, with 2,021 patent records, ahead of Alnylam Pharmaceuticals (1,868) and Massachusetts Institute of Technology (1,636).
Yes, on a multi-year basis. Recent three-year filing volume is roughly double the prior three-year window, confirming a Growth-stage classification. Annual volume peaked in 2023 and has eased since; data for 2024–2025 is further suppressed by publication lag and should not be read as a structural decline.
A61K (medicinal preparations) and C12N (microorganisms and genetic engineering) are the two dominant branches. A61P (therapeutic activity of compounds) ranks third, and C07K (peptides and proteins) is the leading downstream chemistry branch.
The most active co-filing pair is MIT and The Broad Institute, with 605 joint patent records. The Broad Institute and Harvard account for 301, and MIT and Harvard for 277. On the industry side, CRISPR Therapeutics and Bayer Healthcare are the leading pair with 69 joint records.
C12Q (measuring and testing involving enzymes/DNA) and B82Y (nanotechnology applications) are among the lower-share branches adjacent to the dominant LNP core, based on their relative filing density within the corpus. These are observations of comparative sparsity; their value as entry points depends on specific technical goals and competitive context.
Ready to map your own LNP delivery landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.